After peaking at an $8.5 billion valuation in the public market in 2021, 23andMe is at risk of being delisted from the Nasdaq in early 2024 as it’s stock is down 96%. Security breaches impacted 6.9 million users and they have struggled to find a way to keep customers engaged with its products after they’ve used the one-time DNA kit.
